Stada Group
Valentina Novoselova serves as the Head of R&D Finance at STADA since January 2018, providing financial partnership for R&D and Business Development & Licensing, overseeing global pipeline reporting, deal tracking, launch performance, and budgeting for investment projects. Prior to this role, Valentina held multiple positions at STADA CIS from August 2002 to December 2017, including Senior Economist, where responsibilities encompassed budgeting, investment project analysis, and management reporting, alongside notable achievements such as implementing an investment projects database and leading system implementation projects. Valentina holds a CIMA Diploma in Performance Management from PricewaterhouseCoopers Academy and has a background in economics and agricultural sciences from Higher School of Economics and Vjatka State Agricultural Academy, respectively.
This person is not in any teams
This person is not in any offices
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.